Microtransplantation for Acute Myeloid Leukemia: A Systematic Review

被引:5
|
作者
Pan, Bin [1 ]
Lazarus, Hillard M. [2 ]
Gale, Robert Peter [3 ]
机构
[1] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China
[2] Case Western Reserve Univ, Div Hematol & Oncol, Dept Med, Cleveland, OH 44106 USA
[3] Imperial Coll London, Dept Immunol & Inflammat, Haematol Res Ctr, Ducane Rd, London SW7, England
基金
中国国家自然科学基金;
关键词
STEM-CELL MICROTRANSPLANTATION; VERSUS-HOST-DISEASE; BONE-MARROW; ALLOGENEIC SPLEEN; LUNG METASTASES; OLDER PATIENTS; THERAPY; GRAFT; INFUSION; RELAPSE;
D O I
10.1001/jamaoncol.2020.1706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ImportanceThere has been recent interest in microtransplantation of hematopoietic cells to treat hematologic cancers, especially acute myeloid leukemia (AML) and, to a lesser extent, myelodysplastic syndrome (MDS). Most of this interest comes from data from relatively small, uncontrolled clinical trials. ObjectiveTo determine the extent to which published data support the safety and effectiveness of microtransplantation of hematopoietic cells in persons with AML and MDS, examine what clinical data are needed to conclude that microtransplantation is safe and effective, explore microtransplantation's possible mechanisms of action, and determine whether this intervention is appropriately named. Evidence ReviewPubMed was searched from 1966 to April 1, 2020, with the search terms micro-transplantation AND leukemia AND/OR myelodysplastic syndrome with boolean operators. The search identified 14 records; 11 additional records were identified by screening published reviews. A total of 15 records remained after removing duplicates and records without full text, and 14 studies were included in the qualitative synthesis. FindingsAmong the 14 studies including about 600 patients, data from 5 phase 2 studies and 6 case reports of persons with AML included few heterogeneous persons and had obvious selection biases. The single randomized clinical trial also enrolled few persons. There was only 1 phase 2 study of persons with MDS. Point estimates of outcomes in both settings had wide 95% CIs. Conclusions and RelevanceThis study suggests that, to date, there are no convincing data on the safety or effectiveness of microtransplantation in persons with AML or MDS. This strategy should be considered investigational and performed in the setting of controlled clinical trials. This systematic review investigates whether published data support the safety and effectiveness of microtransplantation of hematopoietic cells in persons with acute myeloid leukemia and myelodysplastic syndrome.
引用
收藏
页码:1614 / 1620
页数:7
相关论文
共 50 条
  • [41] SYSTEMATIC REVIEW OF HEALTH STATE UTILITY VALUES FOR ECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA
    Forsythe, A.
    Bal, V.
    Dolph, M.
    Patel, S.
    Tremblay, G.
    [J]. HAEMATOLOGICA, 2017, 102 : 388 - 389
  • [42] Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Lubeck, Deborah P.
    Danese, Mark
    Jennifer, Duryea
    Miller, Kimberly
    Richhariya, Akshara
    Garfin, Phillip M.
    [J]. BLOOD, 2016, 128 (22)
  • [43] Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review
    Blankstein, Anna R.
    Sriranjan, Neelan
    Choi, Nora
    Paulson, Kristjan
    Sanford, David
    Mozessohn, Lee
    Houston, Donald S.
    Rimmer, Emily
    Lother, Sylvain
    Mendelson, Asher
    Garland, Allan
    Buckstein, Rena
    Hay, Annette E.
    Zarychanski, Ryan
    Houston, Brett L.
    [J]. BLOOD, 2022, 140 : 6092 - 6093
  • [44] Hypomethylating agent as first-line treatment for acute myeloid leukemia: Systematic review
    Jhoputri, Caroline Fricilia
    Tandokallo, Felicia
    Kosayuz, Sherina
    Atmaja, William Surya
    Kurniawan, Andree
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1446 - S1446
  • [45] Donor Selection in Human Leukocyte Antigen-Mismatched Hematopoietic Stem Cell Microtransplantation for Acute Myeloid Leukemia
    Hu, Kai-Xun
    Ai, Hui-Sheng
    Guo, Mei
    Yu, Chang-Lin
    Qiao, Jian-Hui
    Sun, Qi-Yun
    Dong, Zheng
    Cai, Bo
    Sun, Wan-Jun
    Wang, Yi
    Zhan, Xinrong
    Liu, Xiangjun
    [J]. STEM CELLS AND DEVELOPMENT, 2020, 29 (10) : 648 - 654
  • [46] Microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia: clinical efficacy and mechanisms analysis
    Jin, Ting
    Gao, Fei
    Yan, Jin
    Jian, Xiao-Rong
    Li, Xiang
    Jiang, Lin
    Wang, Li
    [J]. HEMATOLOGY, 2024, 29 (01)
  • [47] Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
    Hu, Kaixun
    Huang, Yajing
    Ai, Huisheng
    Guo, Mei
    Yu Changlin
    Qiao Jianhui
    Sun, Qiyun
    Dong, Zheng
    Zuo, Hongli
    Cai, Bo
    Shen, Xuliang
    [J]. BLOOD, 2015, 126 (23)
  • [48] HLA-mismatched microtransplantation for relapsed or refractory acute myeloid leukemia as a bridge to allogeneic hematopoietic stem cell transplantation
    Neeraj Sidharthan
    Ephraim Fuchs
    Manoj Unni
    Ullas Mony
    Pavankumar Boyella
    Raghuveer Prabhu
    Rema Ganapathy
    Veena Shenoy
    Geeta Vidyadharan
    [J]. Bone Marrow Transplantation, 2020, 55 : 1684 - 1686
  • [49] Treatments for chronic myeloid leukemia: a qualitative systematic review
    Ferdinand, Roxanne
    Mitchell, Stephen A.
    Batson, Sarah
    Tumur, Indra
    [J]. JOURNAL OF BLOOD MEDICINE, 2012, 3 : 51 - 76
  • [50] Influence of Body Mass Index on Incidence and Prognosis of Acute Myeloid Leukemia and Acute Promyelocytic Leukemia: A Systematic Review and Meta-Analysis
    Li, Shufen
    Chen, Li
    Wang, Kankan
    [J]. BLOOD, 2017, 130